Japan PPI inflation slips to 11-mth low in July
John P. Butler, CEO and President of Akebia Therapeutics (NASDAQ:AKBA), recently sold shares of the company’s common stock, according to a recent SEC filing. On February 3, 2025, Butler sold a total of 144,250 shares at a price of $2.10 each, totaling $302,925. The transaction comes amid a strong performance period for AKBA, with the stock recording a 71.2% gain over the past six months, according to InvestingPro data. This transaction was part of a Rule 10b5-1 trading plan adopted by Butler in December 2023. Following these sales, Butler retains ownership of 2,604,330 shares of Akebia stock, representing a significant stake in the company, which currently has a market capitalization of $467 million. Earlier, on January 31, 2025, Butler acquired additional shares through restricted stock units and stock options, but these transactions were valued at zero dollars per share. For deeper insights into AKBA’s valuation and comprehensive analysis, investors can access the detailed Pro Research Report available on InvestingPro, which covers over 1,400 US stocks.
In other recent news, Akebia Therapeutics has seen significant developments. The company’s drug Vafseo, a treatment for symptomatic anemia caused by chronic kidney disease, received an endorsement from the UK’s National Institute for Health and Care Excellence and approval from the UK Medicines and Healthcare products Regulatory Agency. The drug has also been launched in the U.S. market, with commercial supply agreements providing access for nearly all U.S. dialysis patients.
H.C. Wainwright maintained its Buy rating for Akebia, reflecting confidence in these developments and the company’s market prospects. There are plans for a Phase 3 trial to explore Vafseo’s use in non-dialysis patients, which could further enhance market potential.
Despite a decrease in total revenue in the third quarter of 2024, Akebia remains optimistic about Vafseo’s potential, particularly in the dialysis and non-dialysis chronic kidney disease patient segments. The company reported a net loss of $20 million for the quarter, attributed to increased spending on Vafseo’s prelaunch activities and a decline in revenue from its existing product, AURYXIA. These are among the recent developments at Akebia Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.